





**Veraflo™**  
Therapy

# Start smart for effective and efficient wound care.


3M™ Veraflo™ Therapy makes it  
easier than ever to initiate therapy.



# Delayed healing and wound complications are significant care and cost burdens.



**40%**  
of all wounds are infected or critically colonized.<sup>1</sup>



In the average 500-bed hospital, infected wounds can add 9.58 days in excess length of stay and \$38,656 in excess charges.<sup>2</sup>




Costs are expected to increase even more as the population ages and the incidence of comorbid conditions that give rise to wounds increases.<sup>3</sup>



## A smart start to managing bioburden.

The number of microorganisms with which an object is contaminated is referred to as the bioburden.<sup>4</sup>

### Bioburden formation is commonly considered to occur in five main stages:<sup>5</sup>



# 3M™ Veraflo™ Therapy helps manage bioburden through repeated cleansing cycles.



## Cleanse

Delivers topical wound solutions that dwell in the wound to help dilute and solubilize infectious material.<sup>12</sup>



## Remove

Removes solubilized wound debris and infectious materials under negative pressure to manage bioburden.<sup>13</sup>



## Promote

Promotes granulation tissue formation and perfusion to prepare the wound for closure.<sup>14</sup>



## Reduce

Reduces the number of surgical debridements required when used with either 3M™ Veraflo™ Cleanse Choice Complete™ Dressing or 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing.


# 3M™ Veraflo™ Therapy: Shown to promote granulation tissue formation in a porcine model.



A significant increase in granulation thickness

# 43%\*

( $p=0.05$ ).



Histological images from a porcine study showed a 43% increase in granulation tissue thickness between 3M™ V.A.C.® Therapy with the 3M™ V.A.C.® Granufoam™ Dressing (left) and Veraflo Therapy with the 3M™ V.A.C. Veraflo™ Dressing (right) after 7 days of therapy.<sup>15</sup>

\*Shown to promote granulation tissue formation in porcine studies.

## The first and only negative pressure wound therapy (NPWT) dressings that can hydromechanically remove non-viable tissue.


3M™ Veraflo™ Therapy when used with 3M™ Veraflo™ Cleanse Choice Complete™ Dressing or 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing can help:



Soften



Solubilize



Separate




Remove



Reduce

### 3M™ Veraflo™ Therapy (NPWTi-d).



Veraflo Therapy combines the benefits of V.A.C.® Therapy with an instillation therapy option featuring both **automated volumetric delivery** of topical wound treatment solutions and a **programmable soak feature**, which allows solution to dwell in the wound for thorough contact.

## 3M™ Veraflo™ Therapy has demonstrated positive clinical outcomes over standard of care, including traditional NPWT.<sup>16</sup>

A systematic review of comparative studies and meta-analysis<sup>16</sup> evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients with various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantages over standard of care.



**>30% fewer** surgical debridements.<sup>16,17</sup>

(1.77 debridements vs 2.69,  $p=0.008$ )



Wounds were **2.39 times more likely to close.**<sup>16</sup>

( $p=0.01$ )



**>50% reduced** length of therapy.<sup>16,17</sup>

(9.88 days vs 21.8 days,  $p=0.02$ )




**Reduced** bacterial count from baseline.<sup>16</sup>

(Odds were 4.4 times greater  $p=0.003$ )



Ready for closure almost **twice as fast.**<sup>16,17</sup>

(7.88 days vs 14.36 days,  $p=0.003$ )





## Use of 3M™ Veraflo™ Therapy can potentially reduce costs versus standard of care.

Based upon the meta-analysis by Allen Gabriel, MD et al. an economic model<sup>16</sup> was developed to compare the cost of using Veraflo Therapy to traditional wound care options, including 3M™ V.A.C.® Therapy.

Despite the higher therapy cost of Veraflo Therapy, the reduction in therapy time and required OR visits resulted in a potential savings of 50%, or up to \$33,337 per patient.<sup>17</sup>

### United States



**\$33,337**  
in savings per patient

Overall potential cost saving with NPWTi-d versus control based on fewer OR visits and shorter therapy.

## Can the timing of 3M™ Veraflo™ Therapy initiation help impact outcomes?


Wound complications and their associated costs can increase when treatment is delayed. A retrospective analysis of a national, all-payer hospital database of patients of 514 patients (257 per group)<sup>18</sup> who received Veraflo Therapy in 2019 suggests that early use\* of Veraflo Therapy (within 1 day of NPWT application) compared to late initiation of Veraflo Therapy (within 2-7 days) can help improve clinical outcomes and reduce the cost of care.<sup>18</sup>

- Patients who received Veraflo Therapy on the first day of NPWT required **4.4 fewer days of treatment** than patients who received Veraflo Therapy from day 2 through 7 ( $p < 0.0001$ )<sup>18</sup>
- Patients who received Veraflo Therapy on day 1 **had fewer wound-related readmissions†** than patients receiving late therapy (at 30 days 6 vs. 16;  $p = 0.0293$ , and at 60 days 10 vs. 24;  $p = 0.0130$ )<sup>18</sup>
- The mean **total cost of index admissions was \$10,877 less** for patients who received Veraflo Therapy on day 1, \$34,161 vs. patients who received Veraflo Therapy from day 2 through 7, \$45,038 ( $p < 0.0001$ )<sup>18</sup>


\*Early initiation of Veraflo Therapy was considered on patients who received it as their initial negative pressure treatment or within one day of NPWT application, and late initiation for patients that received Veraflo Therapy within 2-7 days of initial NPWT.

†Admitting, or primary diagnosis, or primary procedure is wound-related, or patient had a HCPCS charge for NPWT.

**Total debridements and time to final OR procedure**



**Length of stay and duration of NPWT**



## 3M™ Veraflo™ Therapy with 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing: Stage IV Pressure Injury

A 64-year-old male presented with a stage 4 pressure injury of the sacrum present for more than four years. Patient comorbidities included: former tobacco use, poor nutritional status, hypertension, chronic paraplegia (more than 15 years), leukocytosis, multiple previous pressure ulcers, and osteomyelitis of the sacrum.

The wound had been treated with NPWT, offloading, silver dressings, air mattress, hydrofiber dressings, alginate dressings, and wound debridement. Sharp debridement was performed but limited by the inability to achieve adequate hemostasis.

NPWT with instillation and V.A.C. Veraflo Cleanse Choice Dressing was initiated. Saline (22mL) was instilled, followed by 1 minute soak time and 30 min of negative pressure at -150mmHg. On day 7, sharp debridement was done at the bedside, removing the tip of the coccyx and non-viable slough/adipose tissue. Two days after the debridement, the therapy was interrupted due to soiling, and the patient underwent colostomy surgery. Three days post-surgery, Veraflo Therapy using the V.A.C. Veraflo Cleanse Choice Dressing was re-started. On day 5, the therapy switched to 3M™ V.A.C.® Therapy at -125mmHg for nine days.

Conservative sharp debridement was performed at the bedside, and oral antibiotics were initiated.

Request the complete clinical study from your 3M Account Representative.

As the wound required further cleansing, Veraflo Therapy using V.A.C. Veraflo Cleanse Choice Dressing was started.

Hypochlorous solution (80-100 mL) was instilled with a 10-minute dwell time, followed by 2 hours of negative pressure at -125 mmHg. Dressing changes occurred every 3 days. After 9 days, Veraflo Therapy was discontinued, and V.A.C.® Therapy was initiated.



### Day 0 of Veraflo Therapy: Wound following bedside sharp debridement.

Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing initiated.

**Dwell time:** 1 minute

**NPWT time:** 30 minutes at -150mmHg

**Solution:** Saline



### Day 3 of Veraflo Therapy:

Wound after first V.A.C. Veraflo Cleanse Choice Dressing change.

#### Specifications

#### References

Patient data and photos courtesy of Kimberly D. Hall, DNP, RN, GCNS-BC, CWCN-AP, COCN and Jessica Patterson, BSN, RN, CWCN

**Note: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.**

## 3M™ Veraflo™ Therapy with 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing: Chronic Wound

A 54-year-old male with hypertension, diabetes mellitus, and Charcot foot was admitted to the hospital with a chronic left foot wound. Patient was treated with an intravenous antibiotic regimen, followed by surgical debridement with excision of necrotic tissue. Veraflo Therapy using V.A.C. Veraflo Cleanse Choice Dressing was applied.

After 14 days and 4 dressing changes, therapy was discontinued. A human dermal collagen matrix was then applied to the wound for closure.



### Day 0 with Veraflo Therapy: V.A.C. Veraflo Cleanse Choice Dressing is used

**Dwell time:** 10 minutes

**NPWT time:** 3.5 hours at -125mmHg

**Solution:** Vashe® Wound Therapy Solution



### Day 2 with Veraflo Therapy:

After the wound bed displayed healthy granulation tissue with minimal devitalized tissue or thick slough, V.A.C. Veraflo Cleanse Choice Dressing was changed.

Request the complete clinical study from your 3M Account Representative.

#### Specifications

#### References

Patient data and photos courtesy of Douglas Duke, DO; Director of Wound Care, Flowers Hospital, Dothan, AL.

**Note: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.**

## 3M™ Veraflo™ Therapy with 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing: Traumatic Wound

A 33-year-old male amputee with history of tobacco use, anemia, and methicillin-resistant *Staphylococcus aureus* presented with infection of above-the-knee stump. Conservative sharp debridement was performed at the bedside, and oral antibiotics were initiated. Veraflo Therapy using V.A.C. Veraflo Cleanse Choice Dressing was started.

Hypochlorous solution (80-100 mL) was instilled with a 10-minute dwell time, followed by 2 hours of negative pressure at -125 mmHg. After 9 days, Veraflo Therapy was discontinued, and 3M™ V.A.C.® Therapy initiated.



### Day 0 of Veraflo Therapy: Wound at presentation

**Dwell time:** 10 minutes

**NPWT time:** 2 hours at -125mmHg

**Solution:** Hypochlorous Solution (80-100mL)



### Day 3 of Veraflo Therapy: Wound after 3 days of Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing use.

Wound after 3 days of Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing.



### Day 6 and 9 of Veraflo Therapy:

Further granulation tissue and reduction in slough after 6 and 9 days of V.A.C. Veraflo Cleanse Choice Dressing. Veraflo Therapy discontinued and switched to V.A.C.® Therapy.

Request the complete clinical study from your 3M Account Representative.

#### Specifications

#### References

Patient data and photos courtesy of Luis Fernandez, MD, FACS, FASAS, FCCP, FCCM, FICS, University of Texas Health Science Center, Tyler, TX

**Note: As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.**

## 3M™ Veraflo™ Therapy with 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing: Traumatic Wound

Following an injury, a 26-year-old female received a transfemoral amputation resulting in a soft tissue defect. During transportation to the facility, the patient had a Combat Tourniquet and received 13 units of packed red blood cells and eight units of fresh frozen plasma. The wound was surgically debrided and irrigated at different stages of the treatment. She received therapeutic plasma exchange, continuous renal replacement therapy after being diagnosed with macrophage activation syndrome, and 3M™ V.A.C.® Therapy at -125mmHg.

When surgical debridement was not an option, Veraflo Therapy was initiated using a V.A.C. Veraflo Cleanse Choice Dressing, instilling 100ml of 0.125% Dakin's Solution to help remove devitalized tissue. As wound healing progressed, Veraflo Therapy was transitioned to using 3M™ V.A.C. Veraflo™ Dressing, instilling 80ml normal saline. After the tangential excision and split-thickness skin graft, it was covered with a non-adherent layer and bolstered using V.A.C.® Therapy applied at -125mmHg. Systemic antibiotics were administered throughout the patient's treatment period.



### Day 0 of Veraflo Therapy:

With patient in critical condition and debridement no longer an option, Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing was initiated.

**Dwell time:** 5 minutes

**NPWT time:** 2 hours at -150mmHg

**Solution:** Dakin's® Solution

Request the complete clinical study from your 3M Account Representative.



### Day 4 of Veraflo Therapy:

Wound demonstrated healing after the use of V.A.C. Veraflo Cleanse Choice Dressing.



### Day 8 of Veraflo Therapy:

Wound showed absence of devitalized tissue, with increase in vascularity and significant granulation. Veraflo Therapy was transitioned to V.A.C. Veraflo Dressing.

## Start smart with 3M™ V.A.C.® Ultra Therapy System.

The only device to provide you with a comprehensive selection of negative pressure wound therapy solutions from a single convenient pump. Empower your outcomes by creating multiple efficiencies across multiple settings.



### Engage the V.A.C.® Ultra Therapy System to:

Streamline

→ Inventory requirements

Standardize

→ Supply protocols

Reduce

→ The number of SKUs required on the shelf

Manage

→ Training time efficiency

Help

→ Clinicians to respond more quickly to patients switching from one negative pressure therapy solution to another

## The 3M™ Smart Instill™ Feature for 3M™ Veraflo™ Therapy.

The Smart Instill Feature uses sophisticated software that automates many of the Veraflo Therapy steps and delivers an easier and less time-consuming interaction when initiating instillation therapy:

### Now with the Smart Instill Feature



Automatically determines the volume of topical wound solution to instill.



Preprogrammed therapy settings align to global advisory recommendations.<sup>19</sup>



Animated troubleshooting, customizable alarm, and postpone feature.


# Therapy initiation steps with the 3M™ Smart Instill™ Feature.

Just another reason to start smart with 3M™ Veraflo™ Therapy.

Select Veraflo Therapy  
↓  
Select Smart Instill Feature



Canister Selection



3M™ Seal Check™ Button/Feature Automated



Fill Estimation Automated



Instillation Automated



Confirmation Optional Automation



# 3M™ Veraflo™ Cleanse Choice Complete™ Dressing Kit.

3M™ Veraflo™ Cleanse Choice Complete™ Dressing foam has an array of 1cm x 8mm hole array providing hydromechanical movement that works in conjunction with the cyclic delivery of instillation fluid and NPWT. This combination creates a purposefully designed hydromechanical movement at the wound bed, which facilitates the stimulation of granulation tissue and removal of solubilized non-viable tissue.

Unique blue foam color makes product identification easy

Two-sided single foam simplifies application

Available in different sizes to minimize waste



Unique two-sided foam reduces the need for multiple SKUs

Facilitates the removal of infectious materials, non-viable tissue and wound debris

## Therapy Goals:



### Cleanse

Cleanse wounds when slough or non-viable tissue remains



### Remove

Hydromechanically remove thick, non-viable tissue and infectious materials



### Promote

Promote granulation tissue formation



### Reduce

Reduces the number of surgical debridements required.


## 3M™ Veraflo™ Cleanse Choice Complete™ Dressing Kit includes 3M™ Dermatac™ Drape.

Innovative silicone-acrylic hybrid material helps with patient comfort at dressing change.



### Apply with ease.

Conforms to different anatomical locations and can be repositioned upon initial placement.



### Seal the heal.

Maintains a highly effective seal for wound protection.



### Remove with kindness.

Skin-friendly removal supports optimal healing and patient comfort over standard of care.

## Feel confident with a skin-friendly drape that maintains a seal for 72 hours.


### Supports the healing process:

- Gentle to the skin and provides peri-wound protection
- Low tack adhesive properties of Dermatac Drape are strong enough to maintain a seal for V.A.C.® Therapy and Veraflo Therapy, yet gentle enough to help take the pain out of dressing changes<sup>20,21,22</sup>
- Easy to use and reduces the time associated with dressing changes compared to standard of care<sup>20,21</sup>

### Improves patient comfort:<sup>23</sup>

Dermatac Drape was placed on 17 patients over a 2-week period, with dressing changes every 48 to 72 hours. At dressing changes, patients were asked how Dermatac Drape felt upon removal.

100% (n=17) of patients agreed that Dermatac Drape was **painless upon removal.**



	3M™ Veraflo™ Cleanse Choice Complete™ Dressing Kit - Medium/Large	3M™ V.A.C. Veraflo Cleanse Choice™ Dressing Kit - Medium/Large	3M™ V.A.C. Veraflo™ Dressing Kit - Small/Medium/Large
<b>SKU</b>	<b>Medium:</b> VFCCC05MD <b>Large:</b> VFCCC05LG 	<b>Medium:</b> ULTVCC05MD <b>Large:</b> ULTVCC05LG 	<b>Small:</b> ULTVFL05SM <b>Medium:</b> ULTVFL05MD <b>Large:</b> ULTVFL05LG 
<b>Wound characteristics</b>	Wounds with thick fibrinous exudate, slough, infectious material, necrotic tissue and other wound bioburden.	Wounds with thick fibrinous exudate, slough, infectious material, necrotic tissue and other wound bioburden.	Open wounds, including wounds with shallow undermining or tunnel areas where the distal aspect is visible.
<b>Key goal(s) of therapy</b>	<ul style="list-style-type: none"> <li>• When used in conjunction with 3M™ Veraflo™ Therapy, to initiate therapy and to help facilitate the hydromechanical removal of infectious materials, non-viable tissue and wound debris</li> <li>• Reduces the number of surgical debridements required, while promoting granulation tissue formation, creating an environment that promotes wound healing.</li> <li>• Helps provide protection for sensitive peri-wound skin</li> </ul>	<ul style="list-style-type: none"> <li>• When used in conjunction with Veraflo Therapy, to initiate therapy and to help facilitate the hydromechanical removal of infectious materials, non-viable tissue and wound debris</li> <li>• Reduces the number of surgical debridements required, while promoting granulation tissue formation, creating an environment that promotes wound healing.</li> </ul>	<ul style="list-style-type: none"> <li>• When used in conjunction with Veraflo Therapy, to help facilitate the removal of infectious material and other wound bioburden</li> <li>• Generation of robust granulation tissue</li> </ul>
<b>Shape</b>	Two-sided single block foam.	Block foam pre-slit in three layers.	<b>Small/Medium:</b> Spiral-cut foam <b>Large:</b> Block foam pre-slit into two layers
<b>Application characteristics</b>	<b>Easy application with flexibility:</b> <ul style="list-style-type: none"> <li>• Single piece foam simplifies application</li> <li>• Patterned array of 1cm holes helps facilitate removal of thick wound exudate</li> <li>• Two-sided foam allows flexibility to accommodate therapy goals</li> <li>• 3M™ Dermatac™ Drape is conformable and easy to apply</li> <li>• Single or duo pad application</li> </ul>	<b>Designed for custom application:</b> <ul style="list-style-type: none"> <li>• Thin layers for improved conformability</li> <li>• Multiple layers provide application options for wounds with varying depths</li> <li>• Ideal for dirty wounds needing active therapy</li> <li>• Single or duo pad application</li> <li>• Patterned array of 1cm holes helps facilitate removal of thick wound exudate</li> </ul>	<b>Small/Medium:</b> <ul style="list-style-type: none"> <li>• Size without scissors</li> <li>• Precut area for pad application when used for bridging</li> <li>• Single pad application</li> </ul> <b>Large:</b> <ul style="list-style-type: none"> <li>• Ideal for large surfaces areas with shallow depths</li> <li>• Provided with 3M™ V.A.C. VeraT.R.A.C. Duo™ Tube Set for extended surface area coverage</li> </ul>

## When therapy goals are achieved with 3M™ Veraflo™ Therapy, step down to other 3M negative pressure wound therapies.

**3M™ V.A.C.® Therapy** – continue negative pressure wound therapy without instillation while in the acute setting. Canisters are available in 500cc or 1000cc.



**3M™ ActiV.A.C.™ Therapy System** – when transitioning patients outside of the hospital choose a portable NPWT solution. Its canister size can hold up to 300cc of exudate.



**3M™ Prevena™ Therapy Single Use Negative Pressure Wound Therapy** – Portable, single-use, disposable therapy unit provides NPWT to help manage closed incisions and low-exuding, small- to medium-sized open wounds. Canisters can hold up to 150 cc of exudate.



3M offers a variety of services to partner with facilities, providers and patients, delivering what is needed most to advance care.



### Order

- Online platform for ordering and inventory management
- Same-day delivery



### Place

- Local clinical, sales, and service support
- Bedside support during product application



### Therapy

- In-home education for dressing changes/alarm resolution
- Mobile app for wound patients
- Digital educational content available on demand



### Discharge

- Seamless on-site support for patients transitioning to Out of Hospital care settings
- Payor authorization assistance
- NPWT telemonitoring for patients' in-home care settings
- Billing management support
- 3M device cleaning, repair, and quality control to minimize downtime

# 3M™ V.A.C.® Ulta Therapy System ordering information for 3M™ Veraflo™ Therapy

Pump & Components		Kits & Dressings	
ULTDEV01/US	3M™ V.A.C.® Ulta Therapy Unit, United States	VFCCC05MD	3M™ Veraflo™ Cleanse Choice Complete™ Dressing Kit, medium, 5-pack
ULTLNK0500	3M™ V.A.C. Veralink™ Cassette, 5-pack	VFCCC05LG	3M™ Veraflo™ Cleanse Choice Complete™ Dressing Kit, large, 5-pack
ULTDUO0500	3M™ V.A.C. VeraT.R.A.C. Duo™ Tube Set, 5-pack	ULTVCC05MD	3M™ V.A.C. Veraflo Cleanse Choice™ Dressing, medium, 5-pack
M8275063/5	500mL Canister with gel for use with 3M™ V.A.C.® Ulta Therapy Unit	ULTVCC05LG	3M™ V.A.C. Veraflo Cleanse Choice™ Dressing, large, 5-pack
M8275093/5	1000mL Canister with gel for use with 3M™ V.A.C.® Ulta Therapy Unit	ULTVCL05MD	3M™ V.A.C. Veraflo Cleanse™ Dressing, medium, 5-pack
		ULTVFL05SM	3M™ V.A.C. Veraflo™ Dressing, small, 5-pack
		ULTVFL05MD	3M™ V.A.C. Veraflo™ Dressing, medium, 5-pack
		ULTVFL05LG	3M™ V.A.C. Veraflo™ Dressing, large, 5-pack
		DTAC10LDP	3M™ Dermatac™ Drape, Case of 10

For more information visit [3M.com/Veraflo](https://www.3m.com/Veraflo)

**Note: Specific indications, contraindications, warnings, precautions, and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals. Rx only.**

**References:**

1. September 2014 Survey, N = 240, Surgeons, Podiatrists, WOCNs and PT
2. Zhan C, Miller MR. Excess Length of Stay, Charges, and Mortality Attributable to Medical Injuries During Hospitalization. *JAMA*. 2003; 290(14): 1868-74.
3. Department of Health (DOH). Comorbidities: A framework of principles for system-wide action. London: DOH, 2014. Accessed March 2019 at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/307143/Comorbidities\\_framework.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/307143/Comorbidities_framework.pdf)
4. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm made easy. London: *Wounds International*. 2017; 8(2).
5. A fact a day – biofilms and wound care. *Wound Source*. 2018.
6. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infection. *Science*. 1999; 284 (5418):1318-1322.
7. Davies DG, Geesey GG. Regulation of the Alginate Biosynthesis Gene algC in *Pseudomonas aeruginosa* during Biofilm Development in Continuous Culture. *Appl Environ Microbiol*. 1995; 61(3):860-867
8. Cicmanec F, Holder IA. Growth of *Pseudomonas aeruginosa* in Normal and Burned Skin Extract: Role of Extracellular Proteases. *Infect Immun*. 1979; 25(2): 477-483.
9. Harrison-Balestra C, Cazzaniga BS, Davis SC, et al. A Wound-Isolated *Pseudomonas aeruginosa* Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy. *Dermatol Surg*. 2003; 29(6):631-635.
10. Schaber JA, Triffo WJ, Suh SJ, et al. *Pseudomonas aeruginosa* Forms Biofilms in Acute Infection Independent of Cell-to-Cell Signaling. *Infect Immun*. 2007; 75(8):3715-3721.
11. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. *J Wound Care*. 2010; 19(8):320-328.
12. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate. *Int Wound J*. 2017;14(5):842-848.
13. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. *Int Wound J*. 2013;10 Suppl 1:56-60.
14. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. *Int Wound J*. 2016;13(2):159-174.
15. Lessing C, Slack P, Hong KZ, Kilpadi D, McNulty A. Negative pressure wound therapy with controlled saline instillation (NPWTi): dressing properties and granulation response in vivo. *Wounds*. 2011 Oct;23(10):309-319.
16. Gabriel A, Camardo M, O'Rorke E, Gold R, Kim PJ. Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis. *Plast Reconstr Surg*. 2021;147(1S-1):68S-76S.
17. Kim PJ, Lookess S, Bongards C, Griffin LP, Gabriel A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. *Int Wound J*. 2021;1-7.
18. Collinworth AW, Griffin LP. The effect of timing of instillation therapy on outcomes and costs for patients receiving negative pressure wound therapy. *Wounds*. 2022;34(11):269-275. doi:10.25270/wnds/22013
19. Kim PJ, Attinger CE, Constantine T, et al. Negative pressure wound therapy with instillation: International consensus guidelines update. *Int Wound J*. 2019;1-13. <https://doi.org/10.1111/iwj.13254>
20. KCI. The Performance of Dermatac™ Drape as compared to V.A.C.® Drape in Healthy Human Subjects. April 5, 2016. KCI. 2015. Dermatac.01.
21. KCI. Summative User Interface Evaluation Report. March 20, 2018.0000046678.
22. KCI. Dermatac Opportunity Assessment: Qualitative & Quantitative Market Research Final Report. October 8, 2015.
23. Galarza, L. (2019, May). Initial clinical observations using a novel negative pressure wound therapy drape comprised of acrylic and silicone. SAWC Spring, San Antonio, TX



**3M Health Care**  
2510 Conway Ave.  
St. Paul, MN 55144 USA

Phone 1-800-228-3957  
Web 3M.com